The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Tocilizumab for the treatment of large‐vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica
Abstract
Objective: The interleukin‐6 pathway is up‐regulated in giant cell arteritis (GCA), Takayasu arteritis (TA), and polymyalgia rheumatica (PMR). We retrospectively assessed the outcomes of 10 patients with relapsing/refractory GCA, TA, or PMR treated with tocilizumab (TCZ). Methods: Patients with GCA (n = 7), TA (n = 2), and PMR (n = 1) received TCZ. Seven subjects had failed at least 1 second‐line agent. The outcomes evaluated were symptoms of disease activity, inflammatory markers, ability to taper glucocorticoids, and cross‐sectional imaging when indicated clinically. Results: The mean followup time of this cohort since diagnosis was 27 months (range 16–60 months). The patients were treated with TCZ for a mean period of 7.8 months (range 4–12 months). Before TCZ therapy, the patients experienced an average of 2.4 flares/year. All patients entered and maintained clinical remission during TCZ therapy. The mean daily prednisone dosages before and after TCZ initiation were 20.8 mg/day (range 7–34.3 mg/day) and 4.1 mg/day (range 0–10.7 mg/day), respectively (P = 0.0001). The mean erythrocyte sedimentation rate declined from 41.5 mm/hour (range 11–68 mm/hour) to 7 mm/hour (range 2.2–11.3 mm/hour; P = 0.0001). The adverse effects of TCZ included mild neutropenia (n = 4) and transaminitis (n = 4). One patient flared 2 months after TCZ discontinuation. An autopsy on 1 patient who died from a postoperative myocardial infarction following elective surgery revealed persistent vasculitis of large and medium‐sized arteries. Conclusion: TCZ therapy led to clinical and serologic improvement in patients with refractory/relapsing GCA, TA, or PMR. The demonstration of persistent large‐vessel vasculitis at autopsy of 1 patient who had shown a substantial response requires close scrutiny in larger studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis
Hunder, G. G., Bloch, D. A., Michel, B. A., Stevens, M. B., Arend, W. P., Calabrese, L. H., Edworthy, S. M., Fauci, A. S., Leavitt, R. Y., Lie, J. T., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330810 · Cited by 2,539
The American College of Rheumatology 1990 criteria for the classification of takayasu arteritis
Arend, W. P., Michel, B. A., Bloch, D. A., Hunder, G. G., Calabrese, L. H., Edworthy, S. M., Fauci, A. S., Leavitt, R. Y., Lie, J. T., Lightfoot, R. W., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330811 · Cited by 2,267
Kerr, G. S., Hallahan, C. W., Giordano, J. M., Leavitt, R. Y., Fauci, A. S., Rottem, M., & Hoffman, G. S. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-11-199406010-00004 · Cited by 1,625
Interleukin-17 and Type 17 Helper T Cells
Miossec, P., Korn, T., & Kuchroo, V. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0707449 · Cited by 1,409
Mechanisms Underlying Lineage Commitment and Plasticity of Helper CD4 + T Cells
O’Shea, J. J., & Paul, W. E. (2010) · Science · doi:10.1126/science.1178334 · Cited by 1,336
Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N., & Kakehi, T. (2008) · Blood · doi:10.1182/blood-2008-05-155846 · Cited by 795
Yokota, S., Imagawa, T., Mori, M., Miyamae, T., Aihara, Y., Takei, S., Iwata, N., Umebayashi, H., Murata, T., Miyoshi, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60454-7 · Cited by 789
EULAR recommendations for the management of large vessel vasculitis
Mukhtyar, C. B., Guillevin, L., Cid, M. C., Dasgupta, B., de Groot, K., Gross, W. L., Hauser, T., Hellmich, B., Jayne, D. R. W., Kallenberg, C. G. M., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.088351 · Cited by 673
Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., & Nishimoto, N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.012 · Cited by 636
Mahr, A. D., Jover, J. A., Spiera, R. F., Hernández‐García, C., Fernández‐Gutiérrez, B., LaValley, M. P., & Merkel, P. A. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22754 · Cited by 622
Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes
Proven, A., Gabriel, S. E., Orces, C., O'Fallon, W. M., & Hunder, G. G. (2003) · Arthritis Care & Research · doi:10.1002/art.11388 · Cited by 612
Hoffman, G. S., Cid, M. C., Hellmann, D. B., Guillevin, L., Stone, J. H., Schousboe, J., Cohen, P., Calabrese, L. H., Dickler, H., Merkel, P. A., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10262 · Cited by 579
Self-citationThe paradigm of IL-6: from basic science to medicine.
Naka, T., Nishimoto, N., & Kishimoto, T. (2002) · Arthritis Research · doi:10.1186/ar565 · Cited by 566
Hoffman, G. S., Cid, M. C., Rendt-Zagar, K. E., Merkel, P. A., Weyand, C. M., Stone, J. H., Salvarani, C., Xu, W., Visvanathan, S., Rahman, M. U., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-9-200705010-00004 · Cited by 563
Self-citationJover, J. A., Hernández-García, C., Morado, I. C., Vargas, E., Bañares, A., & Fernández-Gutiérrez, B. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00010 · Cited by 518
Limitations of therapy and a guarded prognosis in an american cohort of takayasu arteritis patients
Maksimowicz‐McKinnon, K., Clark, T. M., & Hoffman, G. S. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22404 · Cited by 511
Korn, T., Mitsdoerffer, M., Croxford, A. L., Awasthi, A., Dardalhon, V. A., Galileos, G., Vollmar, P., Stritesky, G. L., Kaplan, M. H., Waisman, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809850105 · Cited by 508
Th17 and Th1 T-Cell Responses in Giant Cell Arteritis
Deng, J., Younge, B. R., Olshen, R. A., Goronzy, J. J., & Weyand, C. M. (2010) · Circulation · doi:10.1161/circulationaha.109.872903 · Cited by 435
Treatment of glucocorticoid‐resistant or relapsing takayasu arteritis with methotrexate
Hoffman, G. S., Leavitt, R. Y., Kerr, G. S., Rottem, M., Sneller, M. C., & Fauci, A. S. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370420 · Cited by 409
Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study.
De Silva, M., & Hazleman, B. L. (1986) · Annals of the Rheumatic Diseases · doi:10.1136/ard.45.2.136 · Cited by 360
Treatment of giant cell arteritis: Interleukin-6 as a biologic marker of disease activity
Weyand, C. M., Fulbright, J. W., Hunder, G. G., Evans, J. M., & Goronzy, J. J. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200005)43:5<1041::aid-anr12>3.0.co;2-7 · Cited by 299
Activation of Arterial Wall Dendritic Cells and Breakdown of Self-tolerance in Giant Cell Arteritis
Ma-Krupa, W., Jeon, M.-S., Spoerl, S., Tedder, T. F., Goronzy, J. J., & Weyand, C. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20030850 · Cited by 283
Prognosis and management of polymyalgia rheumatica.
Jones, J. G., & Hazleman, B. L. (1981) · Annals of the Rheumatic Diseases · doi:10.1136/ard.40.1.1 · Cited by 276
Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis
Park, M. C., Lee, S. W., Park, Y. B., & Lee, S. K. (2006) · Rheumatology · doi:10.1093/rheumatology/kei266 · Cited by 251
Spiera, R., Mitnick, H. J., Kupersmith, M. J., Richmond, M., Spiera, H., Peterson, M. G. E., & Paget, S. A. (2001) · PubMed · Cited by 248
Interleukin-6 and RANTES in Takayasu Arteritis: A Guide for Therapeutic Decisions?
Noris, M., Daina, E., Gamba, S., Bonazzola, S., & Remuzzi, G. (1999) · Circulation · doi:10.1161/01.cir.100.1.55 · Cited by 236
Fujimoto, M., Serada, S., Mihara, M., Uchiyama, Y., Yoshida, H., Koike, N., Ohsugi, Y., Nishikawa, T., Ripley, B., Kimura, A., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.24126 · Cited by 225
Tocilizumab: a novel therapy for patients with large-vessel vasculitis
Salvarani, C., Magnani, L., Catanoso, M., Pipitone, N., Versari, A., Dardani, L., Pulsatelli, L., Meliconi, R., & Boiardi, L. (2012) · Rheumatology · doi:10.1093/rheumatology/ker296 · Cited by 225
Salvarani, C., Macchioni, P., Manzini, C., Paolazzi, G., Trotta, A., Manganelli, P., Cimmino, M., Gerli, R., Catanoso, M. G., Boiardi, L., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-9-200705010-00005 · Cited by 199
Rapid induction of remission in large vessel vasculitis by IL-6 blockade
Seitz, M., Reichenbach, S., Bonel, H., Adler, S., Wermelinger, F., & Villiger, P. (2011) · Swiss Medical Weekly · doi:10.4414/smw.2011.13156 · Cited by 190
Nishimoto, N., Nakahara, H., Yoshio‐Hoshino, N., & Mima, T. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23373 · Cited by 180
Interleukin‐21 modulates Th1 and Th17 responses in giant cell arteritis
Terrier, B., Geri, G., Chaara, W., Allenbach, Y., Rosenzwajg, M., Costedoat‐Chalumeau, N., Fouret, P., Musset, L., Benveniste, O., Six, A., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34327 · Cited by 168
Tocilizumab for Rheumatoid Arthritis: A Cochrane Systematic Review
Singh, J. A., Beg, S., & Lopez-Olivo, M. (2011) · Journal of Rheumatology · doi:10.3899/jrheum.100717 · Cited by 156
Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
Matsuyama, M., Suzuki, T., Tsuboi, H., Ito, S., Mamura, M., Goto, D., Matsumoto, I., Tsutsumi, A., & Sumida, T. (2007) · Internal medicine · doi:10.2169/internalmedicine.46.6262 · Cited by 94
García‐Martínez, A., Hernández‐Rodríguez, J., Espígol‐Frigolé, G., Prieto‐González, S., Butjosa, M., Segarra, M., Lozano, E., & Cid, M. C. (2010) · Arthritis Care & Research · doi:10.1002/acr.20043 · Cited by 91
Martínez-Taboada, V. M., Álvarez, L., Ruiz‐Soto, M., Marín-Vidalled, M. J., & López‐Hoyos, M. (2008) · Cytokine · doi:10.1016/j.cyto.2008.09.004 · Cited by 87
Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series
Seitz, M., Reichenbach, S., Bonel, H. M., et al. (2011) · doi:10.7892/boris.2258 · Cited by 80
Haruta, H., Ohguro, N., Fujimoto, M., Hohki, S., Terabe, F., Serada, S., Nomura, S., Nishida, K., Kishimoto, T., & Naka, T. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6272 · Cited by 77
Suzuki, M., Hashizume, M., Yoshida, H., & Mihara, M. (2009) · Rheumatology International · doi:10.1007/s00296-009-0953-0 · Cited by 71
Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica: Figure 1.
Hagihara, K., Kawase, I., Tanaka, T., & Kishimoto, T. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.091185 · Cited by 59
Uchiyama, Y., Yoshida, H., Koike, N., Hayakawa, N., Sugita, A., Nishimura, T., & Mihara, M. (2008) · International Immunopharmacology · doi:10.1016/j.intimp.2008.07.002 · Cited by 52
Thonhofer, R., Hiller, M., Just, H., Trummer, M., Siegel, C., & Dejaco, C. (2011) · Rheumatology International · doi:10.1007/s00296-010-1631-y · Cited by 44
Hatz, H. J., & Helmke, K. (1992) · PubMed · Cited by 13
Cited by
Trial of tocilizumab in giant-cell arteritis
Stone, J. H., Tuckwell, K., Dimonaco, S., Klearman, M., Aringer, M., Blockmans, D., Brouwer, E., Cid, M. C., Dasgupta, B., Rech, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613849 · Cited by 1,386
Self-citationType I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Schwartz, D. M., Bonelli, M., Gadina, M., & O'Shea, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.167 · Cited by 648
Villiger, P. M., Adler, S., Kuchen, S., Wermelinger, F., Dan, D., Fiege, V., Bütikofer, L., Seitz, M., & Reichenbach, S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00560-2 · Cited by 577
Immune mechanisms in medium and large-vessel vasculitis
Weyand, C. M., & Goronzy, J. J. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.161 · Cited by 412
Giant-Cell Arteritis and Polymyalgia Rheumatica
Weyand, C. M., & Goronzy, J. J. (2014) · New England Journal of Medicine · doi:10.1056/nejmcp1214825 · Cited by 410
Metadata
- Authors
- Unizony, S., Arias‐Urdaneta, L., Miloslavsky, E., Arvikar, S., Khosroshahi, A., Keroack, B., Stone, J. R., & Stone, J. H.
- Venue
- Arthritis Care & Research
- Publisher
- Wiley
- Published
- 2012-10-27
- Volume
- 64
- Issue
- 11
- Pages
- 1720-1729
- ISSN
- 0893-7524 (ISSN-L)
- 2151-464X
- 2151-4658
- OpenAlex
- W1989068788
- Cited by
- 272
- References
- 44
- FWCI
- 25.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.